Cynthia M. Rominger

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin, Maureen R. Bleam, Arthur Groy et al. · Clinical Cancer Research · 2011 · 590 citations · Full text

Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors

Dietmar Seiffert, Jodi D. Bradley, Cynthia M. Rominger et al. · Journal of Biological Chemistry · 2000 · 301 citations · Full text

Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic <i>BRAF</i> by the Kinase Inhibitor SB-590885

Alastair J. King, Denis R. Patrick, Roberta S. Batorsky et al. · Cancer Research · 2006 · 262 citations · Full text

Pathology, Oncogenic Braf Alleles, Tumor Biology +17

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia

Ujunwa Cynthia Okoye-Okafor, Boris Bartholdy, Jessy Cartier et al. · Nature Chemical Biology · 2015 · 174 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +8

Discovery of a Novel 2,6-Disubstituted Glucosamine Series of Potent and Selective Hexokinase 2 Inhibitors

Lin Hong, Jin Zeng, Ren Xie et al. · ACS Medicinal Chemistry Letters · 2015 · 84 citations · Full text